Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors

Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortal...

Full description

Saved in:
Bibliographic Details
Published inNephrology (Carlton, Vic.) Vol. 26; no. 5; pp. 377 - 390
Main Authors Scholtes, Rosalie A., Baar, Michaël J. B., Kok, Megan D., Bjornstad, Petter, Cherney, David Z. I., Joles, Jaap A., Raalte, Daniël H.
Format Journal Article
LanguageEnglish
Published Melbourne John Wiley & Sons Australia, Ltd 01.05.2021
Wiley Subscription Services, Inc
Subjects
Angiotensin
Calcium
calcium channel blockers
Calcium Channel Blockers - pharmacology
Calcium Channel Blockers - therapeutic use
Cardiovascular diseases
Clinical trials
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - physiopathology
diabetic kidney disease
Diabetic Nephropathies - prevention & control
Diuretics
Diuretics - pharmacology
Diuretics - therapeutic use
Drug Interactions
Drugs
Glomerular filtration rate
Hemodynamics - drug effects
Humans
Kidney diseases
Morbidity
RAS inhibitors
Renal Circulation - drug effects
Renal function
renal haemodynamic function
Renin
Renin-Angiotensin System - drug effects
Review
Reviews
Risk factors
SGLT2 inhibition
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
type 2 diabetes humans
Vasodilation
diabetic kidney disease
renal haemodynamic function
RAS inhibitors
calcium channel blockers
diuretics
SGLT2 inhibition
type 2 diabetes humans
Online AccessGet full text

Cover

Abstract Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post‐glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin‐angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold‐standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety. SUMMARY AT A GLANCE This invited review describes the renal haemodynamic and protective effects of commonly prescribed drugs in people with type 2 diabetes and their interaction with SGLT2 inhibitors.
AbstractList Diabetic kidney disease remains the leading cause of end-stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium-glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post-glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin-angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold-standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety.
Diabetic kidney disease remains the leading cause of end-stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium-glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post-glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin-angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold-standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety.Diabetic kidney disease remains the leading cause of end-stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium-glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post-glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin-angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold-standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety.
Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post‐glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin‐angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold‐standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety. This invited review describes the renal haemodynamic and protective effects of commonly prescribed drugs in people with type 2 diabetes and their interaction with SGLT2 inhibitors.
Abstract Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post‐glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin‐angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold‐standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety. SUMMARY AT A GLANCE This invited review describes the renal haemodynamic and protective effects of commonly prescribed drugs in people with type 2 diabetes and their interaction with SGLT2 inhibitors.
Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome trials and dedicated kidney trials have shown that sodium‐glucose cotransporter (SGLT)2 inhibitors reduce cardiovascular morbidity and mortality and attenuate hard renal outcomes in patients with type 2 diabetes (T2D). Underlying mechanisms explaining these renal benefits may be mediated by decreased glomerular hypertension, possibly by vasodilation of the post‐glomerular arteriole. People with T2D often receive several different drugs, some of which could also impact the renal vasculature, and could therefore modify both renal efficacy and safety of SGLT2 inhibition. The most commonly prescribed drugs that could interact with SGLT2 inhibitors on renal haemodynamic function include renin‐angiotensin system inhibitors, calcium channel blockers and diuretics. Herein, we review the effects of these drugs on renal haemodynamic function in people with T2D and focus on studies that measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) with gold‐standard techniques. In addition, we posit, based on these observations, potential interactions with SGLT2 inhibitors with an emphasis on efficacy and safety. SUMMARY AT A GLANCE This invited review describes the renal haemodynamic and protective effects of commonly prescribed drugs in people with type 2 diabetes and their interaction with SGLT2 inhibitors.
Author Cherney, David Z. I.
Raalte, Daniël H.
Joles, Jaap A.
Kok, Megan D.
Bjornstad, Petter
Baar, Michaël J. B.
Scholtes, Rosalie A.
AuthorAffiliation 5 Department of Nephrology and Hypertension University Medical Center Utrecht The Netherlands
2 Department of Pediatrics, Division of Endocrinology University of Colorado School of Medicine Aurora Colorado USA
3 Department of Medicine, Division of Nephrology University of Colorado School of Medicine Aurora Colorado USA
1 Amsterdam Diabetes Center, Department of Internal Medicine, Academic Medical Center VU University Medical Center Amsterdam The Netherlands
4 Department of Medicine and Department of Physiology, Division of Nephrology, University Health Network University of Toronto Toronto Ontario Canada
6 Department of Vascular Medicine, Academic Medical Center University of Amsterdam Amsterdam The Netherlands
AuthorAffiliation_xml – name: 5 Department of Nephrology and Hypertension University Medical Center Utrecht The Netherlands
– name: 1 Amsterdam Diabetes Center, Department of Internal Medicine, Academic Medical Center VU University Medical Center Amsterdam The Netherlands
– name: 6 Department of Vascular Medicine, Academic Medical Center University of Amsterdam Amsterdam The Netherlands
– name: 4 Department of Medicine and Department of Physiology, Division of Nephrology, University Health Network University of Toronto Toronto Ontario Canada
– name: 2 Department of Pediatrics, Division of Endocrinology University of Colorado School of Medicine Aurora Colorado USA
– name: 3 Department of Medicine, Division of Nephrology University of Colorado School of Medicine Aurora Colorado USA
Author_xml – sequence: 1
  givenname: Rosalie A.
  surname: Scholtes
  fullname: Scholtes, Rosalie A.
  email: r.scholtes@amsterdamumc.nl
  organization: VU University Medical Center
– sequence: 2
  givenname: Michaël J. B.
  surname: Baar
  fullname: Baar, Michaël J. B.
  organization: VU University Medical Center
– sequence: 3
  givenname: Megan D.
  surname: Kok
  fullname: Kok, Megan D.
  organization: VU University Medical Center
– sequence: 4
  givenname: Petter
  surname: Bjornstad
  fullname: Bjornstad, Petter
  organization: University of Colorado School of Medicine
– sequence: 5
  givenname: David Z. I.
  surname: Cherney
  fullname: Cherney, David Z. I.
  organization: University of Toronto
– sequence: 6
  givenname: Jaap A.
  surname: Joles
  fullname: Joles, Jaap A.
  organization: University Medical Center
– sequence: 7
  givenname: Daniël H.
  orcidid: 0000-0003-2894-6124
  surname: Raalte
  fullname: Raalte, Daniël H.
  organization: University of Amsterdam
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33283420$$D View this record in MEDLINE/PubMed
BookMark eNp1kU1rFTEUhoNU7Icu_AMScKOLafM1k4wLQUqthYuK1nXIzJz0pswk0yTTcv-9qVOLCmaTQ87Dw8l5D9GeDx4QeknJMS3nxMN8TLni7RN0QIUgFZWt3Cs1Z6Sqea320WFK14RQyRr6DO1zzhQXjByg9A28GfHWwBSGnTeT67HxA55jyNBndwsYrC1VwsHiCD6Y9XWIy1XCzuO8mwEzPDjTQYb0Dl_4DPGeCh7fubzF3883l6ygW9e5HGJ6jp5aMyZ48XAfoR8fzy5PP1WbL-cXpx82VS8EbytrgEg1KCEVN4xz0VNLhTWSA1HUsFbVVnSdIpJQWj5vSCe7xoIgUFvTEX6E3q_eeekmGHrwOZpRz9FNJu50ME7_3fFuq6_CrVaENZI3RfDmQRDDzQIp68mlHsbReAhL0kw0UgkuSV3Q1_-g12GJZbWFqknLGJMtK9TblepjSCmCfRyGEn0fpS5R6l9RFvbVn9M_kr-zK8DJCty5EXb_N-nPZ19X5U__kqsJ
CitedBy_id crossref_primary_10_3389_fcvm_2022_1010546
crossref_primary_10_2169_internalmedicine_0107_22
crossref_primary_10_1161_CIRCULATIONAHA_122_061033
crossref_primary_10_2147_DMSO_S448670
crossref_primary_10_1007_s00508_022_02096_x
crossref_primary_10_1053_j_ackd_2021_09_010
crossref_primary_10_1002_ehf2_14313
crossref_primary_10_3390_ijms241814048
crossref_primary_10_3390_ijms22094374
crossref_primary_10_1038_s41581_024_00827_z
Cites_doi 10.1016/S0272-6386(12)80668-8
10.1038/ki.2008.102
10.1016/j.kint.2019.02.033
10.1291/hypres.31.59
10.1016/j.kint.2019.09.023
10.1038/ki.1987.142
10.1038/sj.ki.5001854
10.1056/NEJMoa1812389
10.1001/jama.2014.6634
10.1056/NEJMoa1811744
10.1016/j.kint.2019.03.032
10.1136/bmjopen-2017-018097
10.1016/S2213-8587(15)00417-9
10.1016/j.pcad.2016.10.002
10.1111/j.1523-1755.2004.00620.x
10.2174/1381612811319170012
10.1111/j.1472-8206.2011.01012.x
10.2337/diacare.21.4.597
10.2174/1573402110666140131160617
10.1046/j.1523-1755.1999.055003984.x
10.2310/JIM.0b013e31816d78e9
10.1001/archinte.165.12.1401
10.1056/NEJMoa0802987
10.1016/0168-8227(92)90094-8
10.1046/j.1523-1755.1998.00912.x
10.1007/BF00265402
10.1007/s001250050891
10.7150/ijms.5508
10.1038/hr.2009.184
10.1038/ki.1995.238
10.1681/ASN.2004100852
10.1161/CIRCULATIONAHA.113.005081
10.2215/CJN.11491116
10.1517/14656566.2014.879118
10.1161/CIRCULATIONAHA.120.048739
10.1016/S0140-6736(18)32590-X
10.1080/08037050500230227
10.1016/j.kint.2019.09.013
10.1161/01.HYP.16.3.261
10.1038/sj.jhh.1001279
10.2337/dc11-2189
10.2337/dc11-s247
10.1089/152091502760098456
10.1007/s00125-018-4806-9
10.1056/NEJMoa011303
10.1056/NEJMoa1007994
10.1159/000503712
10.1681/ASN.2016060666
10.1093/eurheartj/ehw132
10.1056/NEJMoa1504720
10.2337/dc11-s246
10.2215/CJN.12391213
10.1056/NEJM199311113292004
10.1056/NEJMoa011489
10.1007/s00125-010-1794-9
10.1177/1074248413501018
10.2337/diacare.23.12.1725
10.2337/dc17-1011
10.2337/diab.32.2.S64
10.1097/HJH.0b013e32834069bd
10.2337/diab.35.11.1206
10.1146/annurev.pharmtox.37.1.361
10.2215/CJN.14831218
10.2215/CJN.10180916
10.1152/ajpregu.00357.2011
10.1056/NEJMoa1911303
10.1161/CIRCHEARTFAILURE.118.005288
10.1007/s00125-012-2485-5
10.1097/00005344-198912000-00009
10.1038/ki.2011.79
10.1016/S0140-6736(03)14739-3
10.1016/0165-6147(88)90070-3
10.1038/sj.bjp.0703829
10.1001/archinte.1993.00410080037006
10.1038/ki.1997.394
10.1042/CS20171298
10.1056/NEJMoa011161
10.1155/2008/305403
10.1681/ASN.V10112382
10.2337/dc18-0394
10.1161/hh1901.097126
10.1007/BF00577736
10.1097/00004872-200205000-00035
10.1016/S0140-6736(12)60987-8
10.1111/dom.12090
10.1016/j.kint.2019.12.021
10.1016/S2213-8587(18)30314-0
10.2337/diacare.28.1.164
10.1046/j.1523-1755.1998.00055.x
10.1038/ki.1997.111
10.1038/ki.1991.249
10.1136/bmj.304.6823.339
10.1056/NEJMoa042167
10.1111/dom.13923
10.1111/dom.12127
10.1590/S0004-27302009000500016
10.1016/j.kint.2016.09.038
10.1007/BF02336678
10.1016/S2213-8587(13)70208-0
10.1016/1056-8727(95)00003-8
10.1111/dom.13754
10.2337/diacare.28.9.2106
10.1016/0002-9149(74)90089-7
10.1177/1074248413497257
10.1007/s00125-009-1268-0
10.1139/y84-065
10.1056/NEJMoa0706245
10.2215/CJN.06080616
10.2991/artres.k.191224.027
10.1016/0002-9343(88)90584-0
10.1536/ihj.49.723
10.1016/S0140-6736(99)12323-7
10.1152/ajprenal.00605.2014
10.1016/S2213-8587(18)30141-4
10.1136/bmj.294.6585.1448
10.1016/j.kint.2017.06.017
10.1016/S2213-8587(15)00030-3
10.2337/dc08-1560
10.1093/ndt/gfs429
10.1038/ki.1992.139
10.1056/NEJMoa1303154
10.1159/000503713
10.1056/NEJMoa1611925
ContentType Journal Article
Copyright 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
2020 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
– notice: 2020 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
– notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7X8
5PM
DOI 10.1111/nep.13839
DatabaseName Wiley-Blackwell Open Access Collection
Wiley Online Library Free Content
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Calcium & Calcified Tissue Abstracts
CrossRef
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley-Blackwell Titles (Open access)
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Scholtes et al
EISSN 1440-1797
EndPage 390
ExternalDocumentID 10_1111_nep_13839
33283420
NEP13839
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: K23 DK116720
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
24P
29M
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
KMS
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOQ
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
XVB
YFH
ZZTAW
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7X8
5PM
ID FETCH-LOGICAL-c4439-fae078d84783a2334c1f14fa73e081a2985f4bb807011839a0b7b6fe40e5fab03
IEDL.DBID DR2
ISSN 1320-5358
1440-1797
IngestDate Tue Sep 17 21:13:02 EDT 2024
Sat Aug 17 04:09:42 EDT 2024
Thu Oct 10 17:55:45 EDT 2024
Fri Aug 23 01:58:14 EDT 2024
Wed Oct 23 09:59:26 EDT 2024
Sat Aug 24 01:04:22 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords diabetic kidney disease
renal haemodynamic function
RAS inhibitors
calcium channel blockers
diuretics
SGLT2 inhibition
type 2 diabetes humans
Language English
License Attribution-NonCommercial
2020 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4439-fae078d84783a2334c1f14fa73e081a2985f4bb807011839a0b7b6fe40e5fab03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Correction added on 20 February, after first online publication: The reference citations have been updated.
ORCID 0000-0003-2894-6124
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fnep.13839
PMID 33283420
PQID 2509222792
PQPubID 2045121
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8026736
proquest_miscellaneous_2467843705
proquest_journals_2509222792
crossref_primary_10_1111_nep_13839
pubmed_primary_33283420
wiley_primary_10_1111_nep_13839_NEP13839
PublicationCentury 2000
PublicationDate May 2021
PublicationDateYYYYMMDD 2021-05-01
PublicationDate_xml – month: 05
  year: 2021
  text: May 2021
PublicationDecade 2020
PublicationPlace Melbourne
PublicationPlace_xml – name: Melbourne
– name: Australia
– name: Richmond
PublicationTitle Nephrology (Carlton, Vic.)
PublicationTitleAlternate Nephrology (Carlton)
PublicationYear 2021
Publisher John Wiley & Sons Australia, Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: John Wiley & Sons Australia, Ltd
– name: Wiley Subscription Services, Inc
References 1984; 62
1987; 31
2019; 96
2013; 369
2019; 14
1975; 12
2015; 308
2018; 41
2008; 31
2016; 37
2013; 9
2014; 129
2001; 132
1997; 51
1989; 32
2020; 97
1997; 52
2019; 21
2015; 373
2014; 15
1999; 55
2008; 358
2014; 19
1988; 85
2012; 26
2019; 393
1994; 72
2011; 364
1992; 41
2010; 33
2019; 7
1992; 262
2000; 355
1990; 38
2011; 80
2020; 142
1992; 304
2008; 56
2002; 4
2012; 35
2017; 377
1996; 10
2014; 311
2016; 4
1987; 294
1995; 47
1997; 37
2008; 49
2020; 22
2018; 93
2005; 16
2018; 11
2005; 14
2004; 65
2006; 70
2017; 40
2017; 7
2010; 53
1993; 329
2013; 28
2019; 50
1990; 16
1986; 35
1992; 17
1994; 24
2012; 59
1998; 41
2001; 89
2008; 73
2005; 28
2012; 55
2008; 2008
2001; 345
2013; 19
2018; 132
2009; 52
2013; 15
2014; 4
2019; 62
2009; 53
2014; 2
2013; 10
1991; 40
1999; 10
2001; 15
1998; 54
2011; 29
1998; 53
2003; 362
1974; 34
1987; 10
2015; 3
2017; 28
2000; 23
2015; 10
2012; 380
1983; 32
2011; 34
2012; 302
2019; 380
1998; 21
2016; 59
2019; 381
2004; 351
2017; 91
2009; 32
2005; 165
2002; 20
1988; 9
2020
2017; 12
2019
2018
1989; 14
1993; 153
e_1_2_9_75_1
e_1_2_9_52_1
e_1_2_9_79_1
e_1_2_9_94_1
e_1_2_9_10_1
e_1_2_9_56_1
e_1_2_9_33_1
e_1_2_9_90_1
e_1_2_9_71_1
Fountain JH (e_1_2_9_40_1) 2020
e_1_2_9_103_1
e_1_2_9_126_1
e_1_2_9_107_1
e_1_2_9_122_1
e_1_2_9_14_1
Biamino G (e_1_2_9_102_1) 1975; 12
e_1_2_9_37_1
e_1_2_9_18_1
e_1_2_9_41_1
e_1_2_9_64_1
e_1_2_9_87_1
e_1_2_9_22_1
e_1_2_9_45_1
e_1_2_9_68_1
e_1_2_9_83_1
e_1_2_9_6_1
e_1_2_9_119_1
e_1_2_9_60_1
e_1_2_9_111_1
e_1_2_9_115_1
e_1_2_9_26_1
e_1_2_9_49_1
e_1_2_9_130_1
e_1_2_9_30_1
e_1_2_9_53_1
e_1_2_9_99_1
e_1_2_9_72_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_57_1
e_1_2_9_95_1
e_1_2_9_76_1
e_1_2_9_91_1
e_1_2_9_129_1
e_1_2_9_106_1
e_1_2_9_125_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_121_1
e_1_2_9_19_1
e_1_2_9_42_1
e_1_2_9_88_1
e_1_2_9_61_1
e_1_2_9_84_1
e_1_2_9_23_1
e_1_2_9_65_1
e_1_2_9_80_1
e_1_2_9_5_1
e_1_2_9_114_1
e_1_2_9_9_1
e_1_2_9_27_1
e_1_2_9_110_1
e_1_2_9_31_1
e_1_2_9_50_1
e_1_2_9_73_1
e_1_2_9_35_1
e_1_2_9_77_1
e_1_2_9_96_1
e_1_2_9_12_1
e_1_2_9_54_1
e_1_2_9_92_1
e_1_2_9_109_1
Price DA (e_1_2_9_69_1) 1999; 10
e_1_2_9_101_1
e_1_2_9_128_1
e_1_2_9_105_1
e_1_2_9_124_1
e_1_2_9_39_1
e_1_2_9_120_1
e_1_2_9_16_1
e_1_2_9_58_1
Horisberger JD (e_1_2_9_104_1) 1987; 10
e_1_2_9_20_1
e_1_2_9_62_1
e_1_2_9_89_1
e_1_2_9_24_1
e_1_2_9_43_1
e_1_2_9_66_1
e_1_2_9_85_1
e_1_2_9_8_1
e_1_2_9_81_1
e_1_2_9_4_1
e_1_2_9_113_1
e_1_2_9_117_1
Collins AJ (e_1_2_9_2_1) 2012; 59
e_1_2_9_28_1
e_1_2_9_47_1
e_1_2_9_132_1
e_1_2_9_74_1
e_1_2_9_51_1
e_1_2_9_78_1
e_1_2_9_13_1
e_1_2_9_32_1
e_1_2_9_55_1
e_1_2_9_97_1
e_1_2_9_93_1
e_1_2_9_108_1
e_1_2_9_70_1
e_1_2_9_127_1
e_1_2_9_100_1
e_1_2_9_123_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_59_1
e_1_2_9_63_1
e_1_2_9_21_1
e_1_2_9_67_1
e_1_2_9_44_1
e_1_2_9_86_1
e_1_2_9_7_1
e_1_2_9_82_1
e_1_2_9_3_1
e_1_2_9_112_1
Denton KM (e_1_2_9_46_1) 1992; 262
Dalal R (e_1_2_9_98_1) 2020
e_1_2_9_116_1
e_1_2_9_25_1
Bolignano D (e_1_2_9_118_1) 2014; 4
e_1_2_9_131_1
e_1_2_9_48_1
e_1_2_9_29_1
References_xml – volume: 26
  start-page: 175
  issue: 2
  year: 2012
  end-page: 179
  article-title: The target‐specific transporter and current status of diuretics as antihypertensive
  publication-title: Fundam Clin Pharmacol.
– volume: 15
  start-page: 527
  issue: 4
  year: 2014
  end-page: 547
  article-title: Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide‐like diuretics
  publication-title: Expert Opin Pharmacother.
– volume: 97
  start-page: 31
  issue: 1
  year: 2020
  end-page: 33
  article-title: Do sodium‐glucose cotransporter‐2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
  publication-title: Kidney Int.
– volume: 73
  start-page: 1303
  issue: 11
  year: 2008
  end-page: 1309
  article-title: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study
  publication-title: Kidney Int.
– volume: 47
  start-page: 1726
  issue: 6
  year: 1995
  end-page: 1731
  article-title: Increased glomerular filtration rate after withdrawal of long‐term antihypertensive treatment in diabetic nephropathy
  publication-title: Kidney Int.
– volume: 132
  start-page: 578
  issue: 2
  year: 2001
  end-page: 586
  article-title: Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na(+)‐glucose cotransporter inhibitor T‐1095
  publication-title: Br J Pharmacol.
– volume: 65
  start-page: 1991
  issue: 6
  year: 2004
  end-page: 2002
  article-title: Differential effects of calcium antagonist subclasses on markers of nephropathy progression
  publication-title: Kidney Int.
– volume: 10
  start-page: 88
  issue: 2
  year: 1996
  end-page: 93
  article-title: Longitudinal evaluation of renal function in non‐insulin‐dependent diabetic patients with early nephropathy: effects of angiotensin‐converting enzyme inhibition
  publication-title: J Diabetes Complications.
– volume: 10
  start-page: 676
  issue: 4
  year: 2015
  end-page: 687
  article-title: Integrated control of Na transport along the nephron
  publication-title: Clin J Am Soc Nephrol.
– volume: 35
  start-page: 2061
  issue: 10
  year: 2012
  end-page: 2068
  article-title: Glomerular hyperfiltration and renal disease progression in type 2 diabetes
  publication-title: Diabetes Care.
– volume: 19
  start-page: 14
  issue: 1
  year: 2014
  end-page: 33
  article-title: Renin‐angiotensin system blocking drugs
  publication-title: J Cardiovasc Pharmacol Ther.
– volume: 132
  start-page: 1329
  issue: 12
  year: 2018
  end-page: 1339
  article-title: SGLT2 inhibition and kidney protection
  publication-title: Clin Sci (Lond).
– volume: 96
  start-page: 283
  issue: 2
  year: 2019
  end-page: 286
  article-title: SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
  publication-title: Kidney Int.
– volume: 302
  start-page: R75
  issue: 1
  year: 2012
  end-page: R83
  article-title: Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
  publication-title: Am J Physiol Regul Integr Comp Physiol.
– volume: 33
  start-page: 11
  issue: 1
  year: 2010
  end-page: 21
  article-title: Reinventing the ACE inhibitors: some old and new implications of ACE inhibition
  publication-title: Hypertens Res.
– volume: 294
  start-page: 1448
  issue: 6585
  year: 1987
  end-page: 1452
  article-title: Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria
  publication-title: Br Med J (Clin Res Ed).
– volume: 49
  start-page: 723
  issue: 6
  year: 2008
  end-page: 732
  article-title: Vasodilatory effect of cilnidipine, an L‐type and N‐type calcium channel blocker, on rat kidney glomerular arterioles
  publication-title: Int Heart J.
– volume: 34
  start-page: S313
  issue: Suppl 2
  year: 2011
  end-page: S319
  article-title: Diuretic treatment of hypertension
  publication-title: Diabetes Care.
– volume: 37
  start-page: 361
  year: 1997
  end-page: 396
  article-title: Molecular determinants of drug binding and action on L‐type calcium channels
  publication-title: Annu Rev Pharmacol Toxicol.
– volume: 355
  start-page: 253
  issue: 9200
  year: 2000
  end-page: 259
  article-title: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO‐HOPE substudy
  publication-title: Lancet
– volume: 53
  start-page: 634
  issue: 5
  year: 2009
  end-page: 645
  article-title: Role of dietary lipids in diabetic nephropathy
  publication-title: Arq Bras Endocrinol Metabol.
– volume: 393
  start-page: 31
  issue: 10166
  year: 2019
  end-page: 39
  article-title: SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta‐analysis of cardiovascular outcome trials
  publication-title: Lancet.
– volume: 59
  start-page: 253
  issue: 3
  year: 2016
  end-page: 261
  article-title: Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?
  publication-title: Prog Cardiovasc Dis.
– volume: 15
  start-page: 849
  issue: 12
  year: 2001
  end-page: 856
  article-title: Effect of two antihypertensive combinations on metabolic control in type‐2 diabetic hypertensive patients with albuminuria: a randomised, double‐blind study
  publication-title: J Hum Hypertens.
– volume: 62
  start-page: 412
  issue: 4
  year: 1984
  end-page: 417
  article-title: Effect of diuretics on the tubuloglomerular feedback response
  publication-title: Can J Physiol Pharmacol.
– volume: 50
  start-page: 345
  issue: 5
  year: 2019
  end-page: 356
  article-title: Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial
  publication-title: Am J Nephrol.
– volume: 7
  issue: 10
  year: 2017
  article-title: Renal and Cardiovascular Effects of sodium‐glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE‐CHF): protocol for a randomised controlled double‐blind cross‐over trial
  publication-title: BMJ Open.
– volume: 351
  start-page: 1941
  issue: 19
  year: 2004
  end-page: 1951
  article-title: Preventing microalbuminuria in type 2 diabetes
  publication-title: N Engl J Med.
– volume: 56
  start-page: 714
  issue: 4
  year: 2008
  end-page: 719
  article-title: Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo‐controlled, double‐blind, crossover trial
  publication-title: J Investig Med.
– volume: 345
  start-page: 851
  issue: 12
  year: 2001
  end-page: 860
  article-title: Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
  publication-title: N Engl J Med.
– volume: 358
  start-page: 580
  issue: 6
  year: 2008
  end-page: 591
  article-title: Effect of a multifactorial intervention on mortality in type 2 diabetes
  publication-title: N Engl J Med.
– volume: 12
  start-page: 751
  issue: 5
  year: 2017
  end-page: 759
  article-title: Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function
  publication-title: Clin J Am Soc Nephrol.
– year: 2019
– volume: 85
  start-page: 344
  issue: 3
  year: 1988
  end-page: 348
  article-title: Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations
  publication-title: Am J Med.
– volume: 2
  start-page: 369
  issue: 5
  year: 2014
  end-page: 384
  article-title: Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double‐blind, placebo‐controlled trial
  publication-title: Lancet Diabetes Endocrinol.
– volume: 14
  start-page: 851
  issue: 6
  year: 1989
  end-page: 855
  article-title: Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy
  publication-title: J Cardiovasc Pharmacol.
– volume: 55
  start-page: 984
  issue: 3
  year: 1999
  end-page: 994
  article-title: Glomerular size‐selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade
  publication-title: Kidney Int.
– volume: 32
  start-page: 40
  issue: 1
  year: 1989
  end-page: 44
  article-title: Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non‐insulin‐dependent) diabetic patients with microalbuminuria: a randomised controlled trial
  publication-title: Diabetologia.
– volume: 19
  start-page: 5
  issue: 1
  year: 2014
  end-page: 13
  article-title: Diuretics: a review and update
  publication-title: J Cardiovasc Pharmacol Ther.
– volume: 4
  start-page: 313
  issue: 3
  year: 2002
  end-page: 321
  article-title: Combination antihypertensive therapy in the treatment of diabetic nephropathy
  publication-title: Diabetes Technol Ther.
– volume: 14
  start-page: 196
  issue: 4
  year: 2005
  end-page: 209
  article-title: Angiotensin receptor blockers: therapeutic targets and cardiovascular protection
  publication-title: Blood Press.
– volume: 32
  start-page: 889
  issue: 5
  year: 2009
  end-page: 893
  article-title: Renal hyperfiltration and the development of microalbuminuria in type 1 diabetes
  publication-title: Diabetes Care.
– volume: 4
  year: 2014
  article-title: Aldosterone antagonists for preventing the progression of chronic kidney disease
  publication-title: Cochrane Database Syst Rev.
– volume: 50
  start-page: 333
  issue: 5
  year: 2019
  end-page: 344
  article-title: Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease Trial
  publication-title: Am J Nephrol.
– volume: 381
  start-page: 1995
  issue: 21
  year: 2019
  end-page: 2008
  article-title: Dapagliflozin in patients with heart failure and reduced ejection fraction
  publication-title: N Engl J Med.
– volume: 129
  start-page: 587
  issue: 5
  year: 2014
  end-page: 597
  article-title: Renal hemodynamic effect of sodium‐glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
  publication-title: Circulation.
– volume: 91
  start-page: 683
  issue: 3
  year: 2017
  end-page: 690
  article-title: Acute change in glomerular filtration rate with inhibition of the renin‐angiotensin system does not predict subsequent renal and cardiovascular outcomes
  publication-title: Kidney Int.
– volume: 9
  start-page: 182
  issue: 3
  year: 2013
  end-page: 186
  article-title: Renal microcirculation and calcium channel subtypes
  publication-title: Curr Hypertens Rev.
– volume: 28
  start-page: 1023
  issue: 4
  year: 2017
  end-page: 1039
  article-title: Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
  publication-title: J Am Soc Nephrol.
– volume: 22
  start-page: 549
  issue: 4
  year: 2020
  end-page: 556
  article-title: The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
  publication-title: Diabetes Obes Metab.
– volume: 59
  issue: 1 Suppl 1
  year: 2012
  article-title: United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end‐stage renal disease in the United States
  publication-title: Am J Kidney Dis
– volume: 34
  start-page: S325
  issue: Suppl 2
  year: 2011
  end-page: S329
  article-title: Monitoring kidney function and albuminuria in patients with diabetes
  publication-title: Diabetes Care.
– volume: 41
  start-page: 912
  issue: 4
  year: 1992
  end-page: 919
  article-title: Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection
  publication-title: Kidney Int.
– volume: 70
  start-page: 2116
  issue: 12
  year: 2006
  end-page: 2123
  article-title: Long‐term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
  publication-title: Kidney Int.
– volume: 21
  start-page: 597
  issue: 4
  year: 1998
  end-page: 603
  article-title: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM
  publication-title: Diabetes Care.
– volume: 41
  start-page: e129
  issue: 8
  year: 2018
  end-page: e130
  article-title: Acute effect of empagliflozin on fractional excretion of sodium and eGFR in youth with type 2 diabetes
  publication-title: Diabetes Care.
– volume: 15
  start-page: 853
  issue: 9
  year: 2013
  end-page: 862
  article-title: Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes
  publication-title: Diabetes Obes Metab.
– year: 2018
  article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes
  publication-title: N Engl J Med.
– volume: 2008
  year: 2008
  article-title: Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats
  publication-title: Exp Diabetes Res.
– volume: 17
  start-page: 191
  issue: 3
  year: 1992
  end-page: 198
  article-title: Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients
  publication-title: Diabetes Res Clin Pract.
– volume: 40
  start-page: 583
  issue: 4
  year: 1991
  end-page: 596
  article-title: Angiotensin actions in the kidney: renewed insight into the old hormone
  publication-title: Kidney Int.
– volume: 37
  start-page: 2105
  issue: 27
  year: 2016
  end-page: 2114
  article-title: A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
  publication-title: Eur Heart J.
– volume: 80
  start-page: 282
  issue: 3
  year: 2011
  end-page: 287
  article-title: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long‐term renal function
  publication-title: Kidney Int.
– volume: 11
  issue: 11
  year: 2018
  article-title: Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction
  publication-title: Circ Heart Fail.
– volume: 93
  start-page: 231
  issue: 1
  year: 2018
  end-page: 244
  article-title: Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
  publication-title: Kidney Int.
– volume: 329
  start-page: 1456
  issue: 20
  year: 1993
  end-page: 1462
  article-title: The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy
  publication-title: The Collaborative Study Group. N Engl J Med.
– volume: 19
  start-page: 3054
  issue: 17
  year: 2013
  end-page: 3059
  article-title: Non‐ACE pathway‐induced angiotensin II production
  publication-title: Curr Pharm Des.
– volume: 10
  start-page: 198
  issue: 3‐4
  year: 1987
  end-page: 220
  article-title: Potassium‐sparing diuretics
  publication-title: Ren Physiol.
– volume: 62
  start-page: 621
  issue: 4
  year: 2019
  end-page: 632
  article-title: The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real‐world observational study
  publication-title: Diabetologia.
– volume: 345
  start-page: 870
  issue: 12
  year: 2001
  end-page: 878
  article-title: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
  publication-title: N Engl J Med.
– volume: 12
  start-page: 2032
  issue: 12
  year: 2017
  end-page: 2045
  article-title: Diabetic kidney disease: challenges, progress, and possibilities
  publication-title: Clin J Am Soc Nephrol.
– volume: 362
  start-page: 1527
  issue: 9395
  year: 2003
  end-page: 1535
  article-title: Blood Pressure Lowering Treatment Trialists C. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials
  publication-title: Lancet.
– volume: 55
  start-page: 1505
  issue: 5
  year: 2012
  end-page: 1513
  article-title: Hyperfiltration in type 1 diabetes: does it exist and does it matter for nephropathy?
  publication-title: Diabetologia.
– volume: 21
  start-page: 1996
  issue: 8
  year: 2019
  end-page: 2000
  article-title: Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials
  publication-title: Diabetes Obes Metab.
– volume: 12
  start-page: 356
  issue: 3
  year: 1975
  end-page: 368
  article-title: Plethysmographic and in vitro studies of the vasodilator effect of furosemide (Lasix)
  publication-title: Int J Clin Pharmacol Biopharm.
– volume: 34
  start-page: 29
  issue: 1
  year: 1974
  end-page: 34
  article-title: Role of diabetes in congestive heart failure: the Framingham study
  publication-title: Am J Cardiol.
– volume: 165
  start-page: 1401
  issue: 12
  year: 2005
  end-page: 1409
  article-title: Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  publication-title: Arch Intern Med.
– volume: 31
  start-page: 1291
  issue: 6
  year: 1987
  end-page: 1298
  article-title: Interlobular arterial resistance: influence of renal arterial pressure and angiotensin II
  publication-title: Kidney Int.
– volume: 16
  start-page: 261
  issue: 3
  year: 1990
  end-page: 268
  article-title: Role of macula densa in diuretics‐induced renin release
  publication-title: Hypertension.
– volume: 14
  start-page: 854
  issue: 6
  year: 2019
  end-page: 861
  article-title: Early glomerular Hyperfiltration and long‐term kidney outcomes in type 1 diabetes: the DCCT/EDIC experience
  publication-title: Clin J Am Soc Nephrol.
– volume: 97
  start-page: 202
  issue: 1
  year: 2020
  end-page: 212
  article-title: The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post‐glomerular vasodilatation rather than pre‐glomerular vasoconstriction in metformin‐treated patients with type 2 diabetes in the randomized, double‐blind RED trial
  publication-title: Kidney Int.
– volume: 52
  start-page: 771
  issue: 3
  year: 1997
  end-page: 777
  article-title: Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition
  publication-title: Kidney Int.
– volume: 35
  start-page: 1206
  issue: 11
  year: 1986
  end-page: 1214
  article-title: Renal effects of nicardipine, a calcium entry blocker, in hypertensive type II diabetic patients with nephropathy
  publication-title: Diabetes.
– volume: 311
  start-page: 2518
  issue: 24
  year: 2014
  end-page: 2531
  article-title: Decline in estimated glomerular filtration rate and subsequent risk of end‐stage renal disease and mortality
  publication-title: JAMA.
– volume: 38
  start-page: 425
  issue: 5
  year: 1990
  end-page: 429
  article-title: Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non‐insulin‐dependent) diabetic patients with and without nephropathy
  publication-title: Eur J Clin Pharmacol.
– volume: 10
  start-page: 1209
  issue: 9
  year: 2013
  end-page: 1216
  article-title: Comparison of the antialbuminuric effects of L‐/N‐type and L‐type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial
  publication-title: Int J Med Sci.
– volume: 31
  start-page: 59
  issue: 1
  year: 2008
  end-page: 67
  article-title: Effect of renin‐angiotensin‐aldosterone system triple blockade on non‐diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin‐converting enzyme inhibitor and angiotensin II receptor blocker
  publication-title: Hypertens Res.
– volume: 52
  start-page: 691
  issue: 4
  year: 2009
  end-page: 697
  article-title: Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta‐analysis
  publication-title: Diabetologia.
– volume: 304
  start-page: 339
  issue: 6823
  year: 1992
  end-page: 343
  article-title: Renal protective effect of enalapril in diabetic nephropathy
  publication-title: BMJ.
– volume: 20
  start-page: 993
  issue: 5
  year: 2002
  end-page: 1000
  article-title: N‐ and L‐type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l‐NAME/SHR model
  publication-title: J Hypertens.
– volume: 262
  start-page: F367
  issue: 3 Pt 2
  year: 1992
  end-page: F372
  article-title: Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli
  publication-title: Am J Physiol.
– volume: 377
  start-page: 644
  issue: 7
  year: 2017
  end-page: 657
  article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes
  publication-title: N Engl J Med.
– volume: 9
  start-page: 416
  issue: 11
  year: 1988
  end-page: 421
  article-title: Molecular sites for diuretic action
  publication-title: Trends Pharmacol Sci.
– volume: 142
  start-page: 1713
  year: 2020
  end-page: 1724
  article-title: Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE‐CHF trial
  publication-title: Circulation.
– volume: 380
  start-page: 2295
  issue: 24
  year: 2019
  end-page: 2306
  article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
  publication-title: N Engl J Med.
– volume: 369
  start-page: 1892
  issue: 20
  year: 2013
  end-page: 1903
  article-title: Combined angiotensin inhibition for the treatment of diabetic nephropathy
  publication-title: N Engl J Med.
– volume: 97
  start-page: 631
  issue: 4
  year: 2020
  end-page: 635
  article-title: Renal hemodynamic effects of sodium‐glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
  publication-title: Kidney Int.
– volume: 96
  start-page: 489
  issue: 2
  year: 2019
  end-page: 504
  article-title: Analysis from the EMPA‐REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
  publication-title: Kidney Int.
– year: 2018
  article-title: Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
  publication-title: Lancet Diabetes Endocrinology.
– volume: 28
  start-page: 405
  issue: 2
  year: 2013
  end-page: 412
  article-title: Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases
  publication-title: Nephrol Dial Transplant.
– volume: 53
  start-page: 1559
  issue: 6
  year: 1998
  end-page: 1573
  article-title: Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers?
  publication-title: Kidney Int.
– volume: 28
  start-page: 2106
  issue: 9
  year: 2005
  end-page: 2112
  article-title: Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double‐masked, cross‐over study
  publication-title: Diabetes Care.
– volume: 345
  start-page: 861
  issue: 12
  year: 2001
  end-page: 869
  article-title: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
  publication-title: N Engl J Med.
– volume: 32
  start-page: 64
  issue: Suppl 2
  year: 1983
  end-page: 78
  article-title: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy
  publication-title: Diabetes.
– volume: 4
  start-page: 211
  issue: 3
  year: 2016
  end-page: 220
  article-title: Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double‐blind, placebo‐controlled, phase 3 study
  publication-title: Lancet Diabetes Endocrinol.
– volume: 10
  start-page: 2382
  issue: 11
  year: 1999
  end-page: 2391
  article-title: The paradox of the low‐renin state in diabetic nephropathy
  publication-title: J Am Soc Nephrol.
– volume: 15
  start-page: 463
  issue: 5
  year: 2013
  end-page: 473
  article-title: Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
  publication-title: Diabetes Obes Metab.
– volume: 380
  start-page: 601
  issue: 9841
  year: 2012
  end-page: 610
  article-title: Diabetes and hypertension: the bad companions
  publication-title: Lancet.
– volume: 153
  start-page: 973
  issue: 8
  year: 1993
  end-page: 980
  article-title: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease
  publication-title: Arch Intern Med.
– volume: 54
  start-page: 889
  issue: 3
  year: 1998
  end-page: 896
  article-title: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy
  publication-title: Kidney Int.
– volume: 364
  start-page: 907
  issue: 10
  year: 2011
  end-page: 917
  article-title: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
  publication-title: N Engl J Med.
– volume: 72
  start-page: 961
  issue: 12
  year: 1994
  end-page: 966
  article-title: Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long‐term study
  publication-title: Clin Investig.
– volume: 308
  start-page: F1026
  issue: 9
  year: 2015
  end-page: F1031
  article-title: Tubuloglomerular and connecting tubuloglomerular feedback during inhibition of various Na transporters in the nephron
  publication-title: Am J Physiol Renal Physiol.
– volume: 28
  start-page: 164
  issue: 1
  year: 2005
  end-page: 176
  article-title: Diabetic nephropathy: diagnosis, prevention, and treatment
  publication-title: Diabetes Care.
– volume: 51
  start-page: 793
  issue: 3
  year: 1997
  end-page: 797
  article-title: de Jong PE. A short‐term antihypertensive treatment‐induced fall in glomerular filtration rate predicts long‐term stability of renal function
  publication-title: Kidney Int.
– volume: 358
  start-page: 2560
  issue: 24
  year: 2008
  end-page: 2572
  article-title: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
  publication-title: N Engl J Med.
– year: 2020
– volume: 29
  start-page: 207
  issue: 2
  year: 2011
  end-page: 216
  article-title: Effects of verapamil added‐on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT‐B randomized trial
  publication-title: J Hypertens.
– volume: 40
  start-page: 1479
  issue: 11
  year: 2017
  end-page: 1485
  article-title: Acute kidney injury in patients on SGLT2 inhibitors: a propensity‐matched analysis
  publication-title: Diabetes Care.
– volume: 3
  start-page: 367
  issue: 5
  year: 2015
  end-page: 381
  article-title: Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
  publication-title: Lancet Diabetes Endocrinol.
– volume: 373
  start-page: 2117
  issue: 22
  year: 2015
  end-page: 2128
  article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
  publication-title: N Engl J Med.
– volume: 41
  start-page: 206
  issue: 2
  year: 1998
  end-page: 211
  article-title: Renal autoregulation is normal in newly diagnosed, normotensive, NIDDM patients
  publication-title: Diabetologia.
– volume: 12
  start-page: 700
  issue: 4
  year: 2017
  end-page: 710
  article-title: SGLT2 inhibition in the diabetic kidney‐from mechanisms to clinical outcome
  publication-title: Clin J Am Soc Nephrol.
– volume: 89
  start-page: 630
  issue: 7
  year: 2001
  end-page: 638
  article-title: Differential expression of T‐ and L‐type voltage‐dependent calcium channels in renal resistance vessels
  publication-title: Circ Res.
– volume: 53
  start-page: 2093
  issue: 10
  year: 2010
  end-page: 2104
  article-title: The clinical significance of hyperfiltration in diabetes
  publication-title: Diabetologia.
– volume: 16
  start-page: 1135
  issue: 4
  year: 2005
  end-page: 1140
  article-title: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes
  publication-title: J Am Soc Nephrol.
– volume: 380
  start-page: 347
  issue: 4
  year: 2019
  end-page: 357
  article-title: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
  publication-title: N Engl J Med.
– volume: 24
  start-page: 753
  issue: 5
  year: 1994
  end-page: 761
  article-title: Long‐term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non‐insulin‐dependent diabetic patients
  publication-title: Am J Kidney Dis.
– volume: 23
  start-page: 1725
  issue: 12
  year: 2000
  end-page: 1730
  article-title: Long‐term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy
  publication-title: Diabetes Care.
– volume: 7
  start-page: 128
  issue: 2
  year: 2019
  end-page: 139
  article-title: Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta‐analysis of treatment effects in randomised clinical trials
  publication-title: Lancet Diabetes Endocrinol.
– ident: e_1_2_9_82_1
  doi: 10.1016/S0272-6386(12)80668-8
– ident: e_1_2_9_111_1
  doi: 10.1038/ki.2008.102
– ident: e_1_2_9_37_1
  doi: 10.1016/j.kint.2019.02.033
– ident: e_1_2_9_117_1
  doi: 10.1291/hypres.31.59
– ident: e_1_2_9_39_1
  doi: 10.1016/j.kint.2019.09.023
– ident: e_1_2_9_45_1
  doi: 10.1038/ki.1987.142
– ident: e_1_2_9_119_1
  doi: 10.1038/sj.ki.5001854
– ident: e_1_2_9_127_1
  doi: 10.1056/NEJMoa1812389
– ident: e_1_2_9_63_1
  doi: 10.1001/jama.2014.6634
– ident: e_1_2_9_24_1
  doi: 10.1056/NEJMoa1811744
– ident: e_1_2_9_38_1
  doi: 10.1016/j.kint.2019.03.032
– volume: 262
  start-page: F367
  issue: 3
  year: 1992
  ident: e_1_2_9_46_1
  article-title: Morphometric analysis of the actions of angiotensin II on renal arterioles and glomeruli
  publication-title: Am J Physiol.
  contributor:
    fullname: Denton KM
– ident: e_1_2_9_131_1
  doi: 10.1136/bmjopen-2017-018097
– ident: e_1_2_9_128_1
  doi: 10.1016/S2213-8587(15)00417-9
– ident: e_1_2_9_58_1
  doi: 10.1016/j.pcad.2016.10.002
– ident: e_1_2_9_88_1
  doi: 10.1111/j.1523-1755.2004.00620.x
– ident: e_1_2_9_42_1
  doi: 10.2174/1381612811319170012
– ident: e_1_2_9_100_1
  doi: 10.1111/j.1472-8206.2011.01012.x
– ident: e_1_2_9_48_1
  doi: 10.2337/diacare.21.4.597
– ident: e_1_2_9_92_1
  doi: 10.2174/1573402110666140131160617
– ident: e_1_2_9_74_1
  doi: 10.1046/j.1523-1755.1999.055003984.x
– ident: e_1_2_9_113_1
  doi: 10.2310/JIM.0b013e31816d78e9
– ident: e_1_2_9_110_1
  doi: 10.1001/archinte.165.12.1401
– ident: e_1_2_9_55_1
  doi: 10.1056/NEJMoa0802987
– ident: e_1_2_9_78_1
  doi: 10.1016/0168-8227(92)90094-8
– ident: e_1_2_9_87_1
  doi: 10.1046/j.1523-1755.1998.00912.x
– ident: e_1_2_9_73_1
  doi: 10.1007/BF00265402
– ident: e_1_2_9_71_1
  doi: 10.1007/s001250050891
– volume: 12
  start-page: 356
  issue: 3
  year: 1975
  ident: e_1_2_9_102_1
  article-title: Plethysmographic and in vitro studies of the vasodilator effect of furosemide (Lasix)
  publication-title: Int J Clin Pharmacol Biopharm.
  contributor:
    fullname: Biamino G
– ident: e_1_2_9_91_1
  doi: 10.7150/ijms.5508
– ident: e_1_2_9_47_1
  doi: 10.1038/hr.2009.184
– ident: e_1_2_9_67_1
  doi: 10.1038/ki.1995.238
– ident: e_1_2_9_75_1
  doi: 10.1681/ASN.2004100852
– ident: e_1_2_9_30_1
  doi: 10.1161/CIRCULATIONAHA.113.005081
– ident: e_1_2_9_3_1
  doi: 10.2215/CJN.11491116
– ident: e_1_2_9_103_1
  doi: 10.1517/14656566.2014.879118
– volume: 10
  start-page: 198
  issue: 3
  year: 1987
  ident: e_1_2_9_104_1
  article-title: Potassium‐sparing diuretics
  publication-title: Ren Physiol.
  contributor:
    fullname: Horisberger JD
– ident: e_1_2_9_132_1
  doi: 10.1161/CIRCULATIONAHA.120.048739
– ident: e_1_2_9_23_1
  doi: 10.1016/S0140-6736(18)32590-X
– ident: e_1_2_9_43_1
  doi: 10.1080/08037050500230227
– ident: e_1_2_9_34_1
  doi: 10.1016/j.kint.2019.09.013
– ident: e_1_2_9_122_1
  doi: 10.1161/01.HYP.16.3.261
– ident: e_1_2_9_89_1
  doi: 10.1038/sj.jhh.1001279
– ident: e_1_2_9_9_1
  doi: 10.2337/dc11-2189
– ident: e_1_2_9_65_1
  doi: 10.2337/dc11-s247
– ident: e_1_2_9_86_1
  doi: 10.1089/152091502760098456
– ident: e_1_2_9_26_1
  doi: 10.1007/s00125-018-4806-9
– ident: e_1_2_9_50_1
  doi: 10.1056/NEJMoa011303
– ident: e_1_2_9_56_1
  doi: 10.1056/NEJMoa1007994
– ident: e_1_2_9_120_1
  doi: 10.1159/000503712
– ident: e_1_2_9_15_1
  doi: 10.1681/ASN.2016060666
– ident: e_1_2_9_116_1
  doi: 10.1093/eurheartj/ehw132
– ident: e_1_2_9_22_1
  doi: 10.1056/NEJMoa1504720
– ident: e_1_2_9_108_1
  doi: 10.2337/dc11-s246
– ident: e_1_2_9_101_1
  doi: 10.2215/CJN.12391213
– ident: e_1_2_9_59_1
  doi: 10.1056/NEJM199311113292004
– ident: e_1_2_9_51_1
  doi: 10.1056/NEJMoa011489
– ident: e_1_2_9_14_1
  doi: 10.1007/s00125-010-1794-9
– ident: e_1_2_9_41_1
  doi: 10.1177/1074248413501018
– ident: e_1_2_9_60_1
  doi: 10.2337/diacare.23.12.1725
– ident: e_1_2_9_129_1
  doi: 10.2337/dc17-1011
– ident: e_1_2_9_7_1
  doi: 10.2337/diab.32.2.S64
– ident: e_1_2_9_54_1
  doi: 10.1097/HJH.0b013e32834069bd
– ident: e_1_2_9_96_1
  doi: 10.2337/diab.35.11.1206
– ident: e_1_2_9_85_1
  doi: 10.1146/annurev.pharmtox.37.1.361
– ident: e_1_2_9_11_1
  doi: 10.2215/CJN.14831218
– ident: e_1_2_9_19_1
  doi: 10.2215/CJN.10180916
– ident: e_1_2_9_32_1
  doi: 10.1152/ajpregu.00357.2011
– ident: e_1_2_9_125_1
  doi: 10.1056/NEJMoa1911303
– ident: e_1_2_9_115_1
  doi: 10.1161/CIRCHEARTFAILURE.118.005288
– ident: e_1_2_9_12_1
  doi: 10.1007/s00125-012-2485-5
– ident: e_1_2_9_72_1
  doi: 10.1097/00005344-198912000-00009
– ident: e_1_2_9_66_1
  doi: 10.1038/ki.2011.79
– ident: e_1_2_9_109_1
  doi: 10.1016/S0140-6736(03)14739-3
– ident: e_1_2_9_99_1
  doi: 10.1016/0165-6147(88)90070-3
– ident: e_1_2_9_21_1
  doi: 10.1056/NEJMoa1812389
– ident: e_1_2_9_31_1
  doi: 10.1038/sj.bjp.0703829
– ident: e_1_2_9_83_1
  doi: 10.1001/archinte.1993.00410080037006
– ident: e_1_2_9_70_1
  doi: 10.1038/ki.1997.394
– ident: e_1_2_9_25_1
  doi: 10.1042/CS20171298
– ident: e_1_2_9_52_1
  doi: 10.1056/NEJMoa011161
– ident: e_1_2_9_33_1
  doi: 10.1155/2008/305403
– volume-title: Physiology
  year: 2020
  ident: e_1_2_9_98_1
  contributor:
    fullname: Dalal R
– volume: 4
  start-page: CD007004
  year: 2014
  ident: e_1_2_9_118_1
  article-title: Aldosterone antagonists for preventing the progression of chronic kidney disease
  publication-title: Cochrane Database Syst Rev.
  contributor:
    fullname: Bolignano D
– volume: 10
  start-page: 2382
  issue: 11
  year: 1999
  ident: e_1_2_9_69_1
  article-title: The paradox of the low‐renin state in diabetic nephropathy
  publication-title: J Am Soc Nephrol.
  doi: 10.1681/ASN.V10112382
  contributor:
    fullname: Price DA
– ident: e_1_2_9_29_1
  doi: 10.2337/dc18-0394
– ident: e_1_2_9_90_1
  doi: 10.1161/hh1901.097126
– ident: e_1_2_9_80_1
  doi: 10.1007/BF00577736
– ident: e_1_2_9_94_1
  doi: 10.1097/00004872-200205000-00035
– ident: e_1_2_9_106_1
  doi: 10.1016/S0140-6736(12)60987-8
– ident: e_1_2_9_17_1
  doi: 10.1111/dom.12090
– ident: e_1_2_9_36_1
  doi: 10.1016/j.kint.2019.12.021
– ident: e_1_2_9_64_1
  doi: 10.1016/S2213-8587(18)30314-0
– ident: e_1_2_9_5_1
  doi: 10.2337/diacare.28.1.164
– ident: e_1_2_9_97_1
  doi: 10.1046/j.1523-1755.1998.00055.x
– ident: e_1_2_9_68_1
  doi: 10.1038/ki.1997.111
– ident: e_1_2_9_44_1
  doi: 10.1038/ki.1991.249
– ident: e_1_2_9_61_1
  doi: 10.1136/bmj.304.6823.339
– ident: e_1_2_9_53_1
  doi: 10.1056/NEJMoa042167
– ident: e_1_2_9_84_1
  doi: 10.1111/dom.13923
– ident: e_1_2_9_28_1
  doi: 10.1111/dom.12127
– volume-title: Physiology
  year: 2020
  ident: e_1_2_9_40_1
  contributor:
    fullname: Fountain JH
– ident: e_1_2_9_10_1
  doi: 10.1590/S0004-27302009000500016
– ident: e_1_2_9_62_1
  doi: 10.1016/j.kint.2016.09.038
– ident: e_1_2_9_95_1
  doi: 10.1007/BF02336678
– ident: e_1_2_9_18_1
  doi: 10.1016/S2213-8587(13)70208-0
– ident: e_1_2_9_81_1
  doi: 10.1016/1056-8727(95)00003-8
– ident: e_1_2_9_130_1
  doi: 10.1111/dom.13754
– ident: e_1_2_9_114_1
  doi: 10.2337/diacare.28.9.2106
– ident: e_1_2_9_107_1
  doi: 10.1016/0002-9149(74)90089-7
– ident: e_1_2_9_105_1
  doi: 10.1177/1074248413497257
– ident: e_1_2_9_8_1
  doi: 10.1007/s00125-009-1268-0
– ident: e_1_2_9_123_1
  doi: 10.1139/y84-065
– ident: e_1_2_9_6_1
  doi: 10.1056/NEJMoa0706245
– ident: e_1_2_9_16_1
  doi: 10.2215/CJN.06080616
– ident: e_1_2_9_35_1
  doi: 10.2991/artres.k.191224.027
– ident: e_1_2_9_77_1
  doi: 10.1016/0002-9343(88)90584-0
– ident: e_1_2_9_93_1
  doi: 10.1536/ihj.49.723
– ident: e_1_2_9_49_1
  doi: 10.1016/S0140-6736(99)12323-7
– ident: e_1_2_9_124_1
  doi: 10.1152/ajprenal.00605.2014
– ident: e_1_2_9_126_1
  doi: 10.1016/S2213-8587(18)30141-4
– ident: e_1_2_9_76_1
  doi: 10.1136/bmj.294.6585.1448
– volume: 59
  start-page: e1‐e420
  issue: 1
  year: 2012
  ident: e_1_2_9_2_1
  article-title: United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end‐stage renal disease in the United States
  publication-title: Am J Kidney Dis
  contributor:
    fullname: Collins AJ
– ident: e_1_2_9_27_1
  doi: 10.1016/j.kint.2017.06.017
– ident: e_1_2_9_4_1
  doi: 10.1016/S2213-8587(15)00030-3
– ident: e_1_2_9_13_1
  doi: 10.2337/dc08-1560
– ident: e_1_2_9_112_1
  doi: 10.1093/ndt/gfs429
– ident: e_1_2_9_79_1
  doi: 10.1038/ki.1992.139
– ident: e_1_2_9_57_1
  doi: 10.1056/NEJMoa1303154
– ident: e_1_2_9_121_1
  doi: 10.1159/000503713
– ident: e_1_2_9_20_1
  doi: 10.1056/NEJMoa1611925
SSID ssj0017261
Score 2.3676875
SecondaryResourceType review_article
Snippet Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome...
Diabetic kidney disease remains the leading cause of end-stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular outcome...
Abstract Diabetic kidney disease remains the leading cause of end‐stage kidney disease and a major risk factor for cardiovascular disease. Large cardiovascular...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 377
SubjectTerms Angiotensin
Calcium
calcium channel blockers
Calcium Channel Blockers - pharmacology
Calcium Channel Blockers - therapeutic use
Cardiovascular diseases
Clinical trials
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - physiopathology
diabetic kidney disease
Diabetic Nephropathies - prevention & control
Diuretics
Diuretics - pharmacology
Diuretics - therapeutic use
Drug Interactions
Drugs
Glomerular filtration rate
Hemodynamics - drug effects
Humans
Kidney diseases
Morbidity
RAS inhibitors
Renal Circulation - drug effects
Renal function
renal haemodynamic function
Renin
Renin-Angiotensin System - drug effects
Review
Reviews
Risk factors
SGLT2 inhibition
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
type 2 diabetes humans
Vasodilation
Title Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fnep.13839
https://www.ncbi.nlm.nih.gov/pubmed/33283420
https://www.proquest.com/docview/2509222792
https://www.proquest.com/docview/2467843705/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC8026736
Volume 26
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9UwEB6VHhAX9iVQKoM4cMlT4iVx4IRQS4VoVZVW6gEpspMx7wnhVG-58OsZO4v6qJAQtyieKIk94_k8nvkM8CZH5XKUMhUWeSqdwrRSqkh1ofOiKlvdylAofHxSHF3Iz5fqcgfej7UwPT_EFHALlhHn62Dgxq6uGbnHq1lO66tQvBeI9AIgOpuoo8gvF_lYIayE0gOrUMjimZ7c9kU3AObNPMnr-DU6oMN78G389D7v5Mdss7az5tcfrI7_-W_34e4ATNmHXpMewA76h3D7eNh6fwSrMwztc4M_u7Y_xp4Z37KB6IEmTTbkhrDOsSX6zvR32-Xm-4otPAvRXsbZGO19x2I0si-sYCEezL5--nLOSXS-sItwCtBjuDg8OP94lA4nNqSNJGSTOoMEOVryeFoYLoRscpdLZ0qBBD0Mr7Ry0lpN80weoJnJbGkLhzIjlTE2E09g13cenwErXIuZUMIKW8pGNpULVIa0eMwk8jIzCbwex66-6ok56nFBQ91Xx-5LYG8c1XqwzVVNoK_ikTgxgVdTM1lV2CoxHrsNyZD_0FKUmUrgaa8E01uEIEgmeZZAuaUek0Bg7N5u8Yt5ZO7W4bwvUSTwNo7-3z-8Pjk4jRfP_130BdzhIeEmZmPuwe56ucGXhJjWdh9ucXm6Hw3kN3nbE2Q
link.rule.ids 230,315,786,790,891,1382,11589,27955,27956,46085,46327,46509,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIgEXxLMEChjEgUtQYo8TB3FBqGWB3VUFW6m3yN6M2T3gVLvd_4_tPNRVhcQtiidK5MmMP49nvgF4l5O0OSGmwhBP0UpKKymLVBUqL6qyUQ2GQuHZvJic4_cLeXEAn4ZamI4fYgy4BcuI_joYeAhIX7NyR5cfcr_Bqm7BbQxEcIHXGc_GM4SSF_lQIyyFVD2vUMjjGR_dX41uQMybmZLXEWxcgk4fwP0eO7LPnbIfwgG5R3Bn1p-OP4btTwrjK01_2qbrNM-0a1jPxeD9GuvTN1hr2YZcq7u7zWb3e8vWjoWALONsCMh-ZDFg2NU-sBCyZb--Thfci67WZh0a9TyB89OTxZdJ2jdVSJfowUdqNXlU0PhFSQnNhcBlbnO0uhTk0YHmlZIWjVHeFeQBPenMlKawhJnXqjaZeAqHrnX0DFhhG8qEFEaYEpe4rGxgG_T7uwyJl5lO4O0wufVlx51RD3sOr4E6aiCB42Ha6958trXHZRWP3IYJvBmH_Y8fTjO0o3bnZbyLVyjKTCZw1GlpfIsQHjUhzxIo9_Q3CgRS7f0Rt15Fcm0VWnKJIoH3UdP__vB6fnIWL57_v-hruDtZzKb19Nv8xwu4x0N-TEyePIbDq82OXnqAc2Vexf_4LyaY9d4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6VIlVcKsozfWEQBy5BiV9x4FS1XQq0qxW0Um-RvbHZPdRZ7Xb_P2Pnoa4qJG5RPFEiT2b8eTzzDcDH3AqXW85TZixNuRM2LYWQqZIql2VRq5qHQuGrsby44T9uxe0WfO1rYVp-iCHgFiwj-utg4IvaPTBybxefc9xflU_gKZeIHAKtM58MRwgFlXlfIiyYUB2tUEjjGR7dXIweIczHiZIPAWxcgUbPYbeDjuSk1fUebFn_AnauusPxl7D6ZcP4TNu7pm4bzRPta9JRMaBbI132BmkcWVrf6PZuvVz_WZG5JyEeSyjp47FfSIwXtqUPJERsye9vl9cURWdzMw99el7Bzej8-vQi7XoqpFOO2CN12iIoqHFNUkxTxvg0dzl3umAWwYGmpRKOG6PQE-QBPOnMFEY6yzNUqjYZew3bvvH2LRDpapsxwQwzBZ_yaekC2SBu7zJuaZHpBD70k1stWuqMqt9yoAaqqIEEDvtprzrrWVUIy0oaqQ0TeD8M438fDjO0t80aZdDDK86KTCTwptXS8BbGEDRxmiVQbOhvEAic2psjfj6L3NoqdORiMoFPUdP__vBqfD6JF_v_L_oOdiZno-ry-_jnATyjITsmpk4ewvb9cm2PEN7cm-P4G_8FqRP1Bw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renal+haemodynamic+and+protective+effects+of+renoactive+drugs+in+type+2+diabetes%3A+Interaction+with+SGLT2+inhibitors&rft.jtitle=Nephrology+%28Carlton%2C+Vic.%29&rft.au=Scholtes%2C+Rosalie+A&rft.au=van+Baar%2C+Micha%C3%ABl+J+B&rft.au=Kok%2C+Megan+D&rft.au=Bjornstad%2C+Petter&rft.date=2021-05-01&rft.issn=1440-1797&rft.eissn=1440-1797&rft.volume=26&rft.issue=5&rft.spage=377&rft_id=info:doi/10.1111%2Fnep.13839&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1320-5358&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1320-5358&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1320-5358&client=summon